In several studies, CEMIP has been confirmed as an oncogene, and the abnormal expression of CEMIP can be detected in most cancer cells, such as prostate cancer (PCa), small cell lung cancer (SCLC), breast cancer, hepatocellular carcinoma (HCC), GC, pancreatic cancer, colon cancer, pancreatic ductal adenocarcinoma (PDAC), and laryngeal squamous cell carcinoma (LSCC) (50, 102–115) (Figure 4A). Here, CEMIP is linked to prostate carcinoma.